

01 July 2021

Our Ref: RFI 39372

Dear

**Freedom of Information Act 2000
Information in relation to Trends in Cancer Treatment**

I am writing to confirm that the South Eastern Health & Social Care Trust (the Trust) has now completed its search for information relating to above which you requested on 7 June 2021.

A response to each of the questions raised has been provided by the Hospital Services Directorate and is attached in Appendix A.

If you are unhappy as to how this request has been handled, you have the right to seek a review within the Trust in the first instance. You should write to the Information Governance Department, Lough House, Ards Community Hospital (informationgovernance@setrust.hscni.net) within two months of the date of this response and your complaint will be considered and a response provided, within 20 working days of receipt.

If, after receiving a response, you remain unhappy, you can refer your complaint to the Information Commissioner at The Information Commissioner's Office –Northern Ireland, 3rd Floor, 14 Cromac Place, Belfast, BT7 2JB. It is important to note that if you refer any matter to the Information Commissioner, you will need to show evidence of having gone through the Trust's internal review procedure to try to resolve the matter with the Trust in the first instance.

If you have any queries about this letter, please do not hesitate to contact me. Please remember to quote the reference number above in any future communications.

Yours sincerely

Rebecca Manning
Information Governance Assistant

Q1. In the past 3 months, how many Urothelial cancer patients were treated with the following:

A1. Please see Table 1.

Table 1

Treatment/Medication	Number of Patients Treated
Atezolizumab	Nil
Carboplatin with Gemcitabine	Nil
Carboplatin single or in any other combination	Nil
Cisplatin with Gemcitabine	Nil
Cisplatin single or in any other combination	Nil
Nivolumab	Nil
Pembrolizumab	<5
Any other regimen including Paclitaxel	Nil
Any other chemotherapy regimen	Nil
Other active systemic anti-cancer therapy	Nil
Palliative care only	Nil

NB. You will note that some of the numbers have been masked and this is due to small numbers within a small geographical area.

Q2. Does your trust participate in any ongoing clinical trials for the treatment of urothelial cancer? If so, can you please provide the name of each trial along with the number of patients taking part?

A2. No, the Trust does not participate in any clinical trials for the treatment of urothelial cancer.

Q3. In the past 3 months, how many non-small cell lung cancer (NSCLC) patients were treated with:

A3. Please see Table 2.

Table 2

Treatment/Medication	Number of Patients Treated
Afatinib	Nil
Alectinib	<5
Atezolizumab monotherapy	5
Atezolizumab + Bevacizumab + Carboplatin + Paclitaxel	Nil
Bevacizumab	Nil
Brigatinib	Nil
Ceritinib	Nil
Crizotinib	<5
Dacomitinib	Nil
Dabrafenib with Trametinib	Nil
Docetaxel	<5
Durvalumab	Nil
Erlotinib	Nil
Gefitinib	<5
Gemcitabine	Nil
Nintedanib with Docetaxel	<5
Nivolumab	<5
Osimertinib	<5
Paclitaxel	Nil
Pembrolizumab monotherapy	5
Pembrolizumab chemo in combination	<5
Pemetrexed with Carboplatin	<5
Pemetrexed with Cisplatin	Nil
Vinorelbine and cisplatin/carboplatin	Nil
Any other active systemic anti-cancer therapy	Nil
Palliative care only	Nil

NB. You will note that some of the numbers have been masked and this is due to small numbers within a small geographical area.

Q4. Does your trust participate in any ongoing clinical trials for the treatment of non-small cell lung cancer (NSCLC)? If so, can you please provide the name of each trial along with the number of patients taking part?

A4. No, the Trust does not participate in any clinical trials for the treatment of NSCLC.